| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T155 |
0-9 |
Sentence |
denotes |
Figure 4. |
| T156 |
11-94 |
Sentence |
denotes |
Treatments for targeting coronavirus disease 2019 (COVID-19)-associated thrombosis. |
| T157 |
95-291 |
Sentence |
denotes |
Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH), bind antithrombin (AT), and potentiate the inhibitory effect of AT on coagulation factors Xa and thrombin. |
| T158 |
292-627 |
Sentence |
denotes |
Furthermore, UFH may have antiviral effects by having the ability to bind the receptor-binding domain of the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in addition to potentially acting as a decoy for naturally expressed heparan sulfate thus reducing the ability of the virus to bind to and invade cells. |
| T159 |
628-752 |
Sentence |
denotes |
The putative anti-inflammatory effects of UFH is related to its ability to bind danger-associated molecular pattern (DAMPs). |
| T160 |
753-902 |
Sentence |
denotes |
Inhibitors of FXII block the contact factor pathway of coagulation, initiated by NETs, and also appear to have pleiotropic anti-inflammatory effects. |
| T161 |
903-1108 |
Sentence |
denotes |
Antiplatelet agents, such as dipyridamole, nafamostat, and aspirin inhibit platelet activation, which can inhibit NETosis and the release of platelet-derived DAMPs such as HMGB (high mobility group box)-1. |
| T162 |
1109-1212 |
Sentence |
denotes |
Nafamostat may inhibit the TMPRSS-2 (transmembrane protease serine 2) and therefore impede viral entry. |
| T163 |
1213-1305 |
Sentence |
denotes |
Fibrinolytics, such as tPA (tissue-type plasminogen activator), degrade cross-linked fibrin. |
